Use of multiple antigenic peptides related to antigenic determinants of infectious bursal disease virus (IBDV) for detection of anti-IBDV-specific antibody in ELISA—quantitative comparison with native antigen for their use in serodiagnosis

Saravanan, P.; Kumar, Satish; Kataria, J.M.

doi:10.1016/j.jim.2004.07.001

Cited by 25 publications

(27 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In case of immobilizing MAPs on a solid phase, a large number of epitopic peptides may coat the surface and present the epitope analog efficiently to the binding of antibodies, leading to higher reactivity at lower concentration (Saravanan et al 2004). As compared to linear peptides, MAP8 was reported to increase the detection sensitivity approximately 1000 times in solidphase immunoassays (Kim and Pau 2001).…”

Section: Discussionmentioning

confidence: 99%

“…Multiple antigen peptides (MAPs), which contain monomeric peptides or different branching peptides, can be synthesized chemically on the second to eighth branches of a lysine framework (Tam 1988;Ahlborg 1995;Tam 1996). When MAPs were used as antigens in immunoassays for detection of antibodies in serum samples, the reactivity of the antigen epitopes would significantly increase (Saravanan et al 2004;Kim and Pau 2001). In this project, a novel enzyme immunoassay based on MAP8 coupled magnetic beads was established, and particularly, the potential of regeneration of the immunomagnetic beads was investigated.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Reusable immunomagnetic beads in an enzyme immunoassay

Han

Luo

Guo

et al. 2007

World J Microbiol Biotechnol

View full text Add to dashboard Cite

Multiple antigen peptides (MAPs) were synthesized according to the epitope sequence of human cytomegalovirus phosphoprotein pp150 and used as antigens to coat the surface of Dynabeads M-450 Tosylactivated covalently. The coating efficiency peaked at 79% when the concentration of MAP8 was 100 lg/ml. Based on the immunomagnetic beads, an enzyme immunoassay was established to detect anti-MAP8 immunoglobulin G in sera of Balb/c mice, which were immunized with MAP8. We showed in this study that, with optimized working conditions, the immunomagnetic beads could be regenerated after removal of the antibody complexes from their surface with 0.2 M citric acid buffer (pH 2.5) and reused at least 16 times without significantly influencing the antibody binding efficiency. The results suggest the possibility of developing reusable immuno-diagnostic kits in the near future.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Reusable immunomagnetic beads in an enzyme immunoassay

Han

Luo

Guo

et al. 2007

World J Microbiol Biotechnol

View full text Add to dashboard Cite

show abstract

“…Also, the synthesis of peptide can be standardized easily according to industrial standards. Many research institutes are developing the application of multiple antigenic peptides in the field of diagnosis [23][24][25] . With the advance of the peptide synthesis technique and the research of microbial antigenic epitopes, it is imaginable that this simple parallel analytical method still has great potential to be applied for more purposes, such as microbial typing and analysis of epitopes, in the near future.…”

Section: Discussionmentioning

confidence: 99%

A Simple Parallel Analytical Method of Prenatal Screening

Li¹,

Yang²,

Zhang³

et al. 2006

Gynecol Obstet Invest

View full text Add to dashboard Cite

Protein microarray has progressed rapidly in the past few years, but it is still hard to popularize it in many developing countries or small hospitals owing to the technical expertise required in practice. We developed a cheap and easy-to-use protein microarray based on dot immunogold filtration assay for parallel analysis of ToRCH-related antibodies including Toxoplasma gondii, rubella virus, cytomegalovirus and herpes simplex virus type 1 and 2 in sera of pregnant women. It does not require any expensive instruments and the assay results can be clearly recognized by the naked eye. We analyzed 186 random sera of outpatients at the gynecological department with our microarray and commercial ELISA kit, and the results showed there was no significant difference between the two detection methods. Validated by clinical application, the microarray is easy to use and has a unique advantage in cost and time. It is more suitable for mass prenatal screening or epidemiological screening than the ELISA format.

show abstract

“…Advanced malignant tumors are often characterized by invasion and metastasis (1). The prognosis of patients with tumor metastasis is very poor, and metastasis continues to be a major cause of mortality in patients with tumors.…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, inhibition of heparanase significantly reduced invasion and metastasis of tumor cells (3,(11)(12)(13), and several potent heparanase inhibitors have shown promising efficacy at the preclinical stage. One of representative heparanase inhibitors, PI-88, has been evaluated in a multicenter phase II or III clinical trial (1,6), but due to the multiple biologic activities of heparanase inhibitors, the mechanism of their antitumor activity and their relation with heparanase inhibition are not clear; therefore, the application of heparanase inhibitors in the clinic may require further studies (14). Accumulating evidence suggests that heparanase can serve as a universal TAA for the immunotherapy of cancer (7,(15)(16)(17)(18)(19)(20).…”

Section: Introductionmentioning

confidence: 99%

Multiple Antigenic Peptides Based on H-2Kb–Restricted CTL Epitopes from Murine Heparanase Induce a Potent Antitumor Immune ResponseIn Vivo

Tang

Wang

Guo

et al. 2012

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Accumulating research suggests that heparanase may be a universal tumor-associated antigen (TAA). Several heparanase T-cell epitopes from humans and mice have already been identified. However, because of low immunogenicity, polypeptide vaccines usually have difficulty inducing effective antitumor immune responses in vivo. In this study, to increase the immunogenicity of polypeptide vaccines, we designed and synthesized two four-branch multiple antigenic peptides (MAP) on the basis of mouse heparanase (mHpa) Tcell epitopes (mHpa398 and mHpa519). The dendritic cells (DC) from mice bone marrow loaded with above MAP vaccines from heparanase were used to evaluate immune response against various tumor cell lines, compared with immune response to their corresponding linear peptides, ex vivo and in vivo. We further assessed IFN-g release both in CD4 þ T-cell-depleted and nondepleted mice. The results showed that effectors generated from DCs, loaded with MAP-vaccinated mice splenocytes, induced a stronger immune response against target cells expressing both heparanase and H-2K b than did effectors generated from mice vaccinated with their corresponding linear peptides. Heparanase-specific CD8 þ T-cell responses induced by MAP and linear peptide vaccination required synergy of CD4 þ T cells. In addition, heparanse-derived MAP vaccines significantly inhibited the growth of B16 murine melanoma in C57BL/6 mice, while also increasing the survival rate of tumor-bearing mice. Our data suggest that MAP vaccines based on T-cell epitopes from heparanase are efficient immunogens for tumor immunotherapy.

show abstract

Use of multiple antigenic peptides related to antigenic determinants of infectious bursal disease virus (IBDV) for detection of anti-IBDV-specific antibody in ELISA—quantitative comparison with native antigen for their use in serodiagnosis

Cited by 25 publications

References 20 publications

Reusable immunomagnetic beads in an enzyme immunoassay

Reusable immunomagnetic beads in an enzyme immunoassay

A Simple Parallel Analytical Method of Prenatal Screening

Multiple Antigenic Peptides Based on H-2Kb–Restricted CTL Epitopes from Murine Heparanase Induce a Potent Antitumor Immune ResponseIn Vivo

Contact Info

Product

Resources

About